G&A

SeaStar Medical Reports 2023 Financial Results and Provides a Business Update

Retrieved on: 
Mercredi, avril 17, 2024
Mortality, FDA, Nephrology, Risk, Nephron, Partnership, Hepatorenal syndrome, Acute kidney injury, ICU, White, AKI, Chronic kidney disease, Monocyte, Heart failure, SCD, Dialysis, CRRT, CKRT, KRT, Inflammation, Safety, Insurance, Clinical study design, Therapy, Clinical trial, G&A, Sepsis, University, HDE, Survival rate, Neutrophil, Acute respiratory distress syndrome, Patent, Cardiorenal syndrome, European Journal, Physician, Manuscript, Bank statement, Standard of care, Pharmaceutical industry

DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.

Key Points: 
  • DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.
  • “Lastly, I’m pleased that we have filed our Form 10-K for 2023, which includes restated 2022 financial statements,” said Mr. Schlorff.
  • Mr. Green brings to SeaStar Medical extensive financial experience at public medical device and therapeutics companies.
  • The Company reported cash of $176,000 as of December 31, 2023, compared with $47,000 as of December 31, 2022.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Lundi, avril 15, 2024
Sale, Idiopathic pulmonary fibrosis, Weill Cornell Medicine, University, Internal, Research and development, Epithelium, Investment, Fibroblast, Interstitial, Pleural effusion, IPF, LPE, Intensive care medicine, Administration, University of Giessen, University of Alabama, Patient, Acquisition, Fibrosis, Associate, Series, Therapy, G&A, Critical Care Medicine (journal), ALRN, Pharmaceutical industry

AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • We expect to report topline results from the ongoing Phase 1b study of LTI-03 in the third quarter of this year.
  • Net Loss: Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.

PetMeds® Announces Fiscal 2024 Third Quarter Financial Results and Completion of Financial Restatement

Retrieved on: 
Lundi, avril 15, 2024
CFO, Investment, ASC, Annual report, Hand, Acquisition, Trust, Adjustment, Bank statement, G&A

DELRAY BEACH, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS)(“PetMeds” or “Company”), Your Trusted Pet Health ExpertTM, today announced its financial results for its third quarter of fiscal year 2024, restated financial statements for the years ended March 31, 2023, 2022 and 2021, and interim financial statements for previously reported quarterly periods in 2023 and 2022.

Key Points: 
  • This compares to net loss of $212 thousand, or $(0.01) diluted earnings per share, for the prior year quarter ended December 31, 2022.
  • Adjusted EBITDA1 of $924 thousand for the current year fiscal third quarter, compared to Adjusted EBITDA of $2.7 million, for the quarter ended December 31, 2022.
  • This restatement does not have any impact on our anticipated fiscal 2024 revenue or gross margins or on our cash position as of December 31, 2023.
  • Due to limitations in NOLs, deferred tax assets decreased, and goodwill increased in the first three quarters of fiscal 2024.

World Acceptance Corporation Reports Fiscal 2024 Fourth Quarter Results

Retrieved on: 
Jeudi, mai 2, 2024
Banking, Other Professional Services, Professional Services, Finance, Acquisition, G&A, Security (finance)

As a percentage of revenues, G&A expenses decreased from 45.5% during the fourth quarter of fiscal 2023 to 45.0% during the fourth quarter of fiscal 2024.

Key Points: 
  • As a percentage of revenues, G&A expenses decreased from 45.5% during the fourth quarter of fiscal 2023 to 45.0% during the fourth quarter of fiscal 2024.
  • G&A expenses per average open branch increased by 0.5% when comparing the fourth quarter of fiscal 2024 to the fourth quarter fiscal 2023.
  • Personnel expense decreased $2.2 million, or 4.7%, during the fourth quarter of fiscal 2024 as compared to the fourth quarter of fiscal 2023.
  • Incentive expense decreased $1.3 million, or 14.1%, in the fourth quarter of fiscal 2024 compared to the fourth quarter of fiscal 2023.

FCPT Announces First Quarter 2024 Financial and Operating Results

Retrieved on: 
Mercredi, mai 1, 2024
REIT, Restaurant, Bar, Retail, Commercial Building & Real Estate, Construction & Property, Collection, ATM, FFO, Common stock, Term loan, Credit, G&A, Interest, Security (finance)

Four Corners Property Trust, Inc. (“FCPT” or the “Company”, NYSE: FCPT) today announced financial results for the three months ended March 31, 2024.

Key Points: 
  • Four Corners Property Trust, Inc. (“FCPT” or the “Company”, NYSE: FCPT) today announced financial results for the three months ended March 31, 2024.
  • NAREIT-defined FFO per diluted share for the first quarter was $0.41, representing a $0.02 increase compared to the same quarter in 2023.
  • AFFO per diluted share for the first quarter was $0.43, representing a $0.02 per share increase compared to the same quarter in 2023.
  • FCPT declared a dividend of $0.345 per common share for the first quarter of 2024.

G&A Partners Acquires Utah-based PEO, Teamworks Group

Retrieved on: 
Mardi, avril 30, 2024
Consulting, Professional Services, Other Professional Services, Small Business, Human Resources, University, HRO, Partner, Docent, Acquisition, Brigham Young University, PEO, G&A

Founded by David McDougal, Teamworks Group has been providing exceptional customer service and strategic HR solutions to small businesses since 1996.

Key Points: 
  • Founded by David McDougal, Teamworks Group has been providing exceptional customer service and strategic HR solutions to small businesses since 1996.
  • The PEO has experienced substantial growth under the leadership of Chief Executive Officer Morgan Taylor and Chief Operating Officer Marshall Paxson who, prior to joining Teamworks Group, founded Docent HR.
  • Teamworks Group and Docent HR merged in January 2020.
  • This, in turn, gives them the time and resources to grow.”
    Taylor and Paxson will continue to support the Teamworks Group staff and clients.

Franklin Street Properties Corp. Announces First Quarter 2024 Results

Retrieved on: 
Mardi, avril 30, 2024
Commercial Building & Real Estate, Construction & Property, REIT, Sale, Internet, Net income, Note 2, Franklin Street, VIE, News, Alert messaging, Investment, Monument, Webcast, Financial instrument, FFO, Foot, Sun Belt, Funds from operations, Consolidated, Current research information system, Sponsor, Bank statement, FSP, GAAP, G&A, Note

Franklin Street Properties Corp. (the “Company”, “FSP”, “we” or “our”) (NYSE American: FSP), a real estate investment trust (REIT), announced its results for the first quarter ended March 31, 2024.

Key Points: 
  • Franklin Street Properties Corp. (the “Company”, “FSP”, “we” or “our”) (NYSE American: FSP), a real estate investment trust (REIT), announced its results for the first quarter ended March 31, 2024.
  • G&A expenses for the first quarter of 2024 were $0.3 million higher than the first quarter of 2023.
  • Today’s news release, along with other news about Franklin Street Properties Corp., is available on the Internet at www.fspreit.com .
  • A conference call is scheduled for May 1, 2024, at 11:00 a.m. (ET) to discuss the first quarter 2024 results.

MorphoSys AG Reports First Quarter 2024 Financial Results

Retrieved on: 
Lundi, avril 29, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Sale, FDA, Bone marrow, BET, Research and development, EDT, Investment, Safety, JAK, Food, EZH1, Research, Marketing, EZH2, Administration, ASCO, Novartis, Ruxolitinib, Patient, Supervisory board, Society, Acquisition, Operating cost, Annual general meeting, G&A, European Medicines Agency

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
  • The financial results presented for the first quarter of 2024 relate to continuing business operations of MorphoSys.
  • Full Year 2024 Financial Guidance:
    As a consequence of the sale and transfer of tafasitamab to Incyte on February 5, 2024, MorphoSys' 2024 financial guidance published on January 30, 2024, cannot be maintained and therefore was revoked.
  • MorphoSys Group Key Figures (IFRS, end of the first quarter: March 31, 2024)

NETSTREIT Reports First Quarter 2024 Financial and Operating Results

Retrieved on: 
Lundi, avril 29, 2024
Other Construction & Property, Commercial Building & Real Estate, Construction & Property, REIT, G&A, GAAP

On April 23, 2024, the Company’s Board of Directors declared a quarterly cash dividend of $0.205 per share for the second quarter of 2024.

Key Points: 
  • On April 23, 2024, the Company’s Board of Directors declared a quarterly cash dividend of $0.205 per share for the second quarter of 2024.
  • The dividend will be paid on June 14, 2024 to shareholders of record on June 3, 2024.
  • The Company's 2024 guidance is based on a number of assumptions that are subject to change and many of which are outside the Company's control.
  • During the conference call the Company’s officers will review first quarter performance, discuss recent events, and conduct a question and answer period.

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Mercredi, avril 10, 2024
Abele, AAAAI, FDA, Citizenship, Research, Healthcare Improvement Scotland, Trial of the century, SMC, IND, Record, Intellectual property, National Congress, American Academy, Attack, Food, ACAAI, Conference, Hereditary angioedema, MHRA, HAE, Therapy, Network, EOP, Book, PRO, Chemistry, CMC, G&A, Investigational New Drug, Doctor of Philosophy, Medication, Research and development, American College, Mass meeting, Health care, Administration, Bank statement, Annual general meeting, Heredity, Pharmaceutical industry

Pharvaris is currently enrolling in RAPIDe-3, a global pivotal Phase 3 study of deucrictibant immediate-release capsule (PHVS416) for the on-demand treatment of HAE attacks.

Key Points: 
  • Pharvaris is currently enrolling in RAPIDe-3, a global pivotal Phase 3 study of deucrictibant immediate-release capsule (PHVS416) for the on-demand treatment of HAE attacks.
  • Effective April 15, 2024, David Nassif, J.D., will join Pharvaris as Chief Financial Officer and will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations.
  • Loss for the fourth quarter of 2023 was €32.7 million, resulting in basic and diluted loss per share of €0.74.
  • Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.